Portola Pharmaceuticals has entered a partnership with Bayer HealthCare and Johnson & Johnson's Janssen Pharmaceuticals to support a midstage clinical trial of PRT-4445, a reversal agent for anticoagulant Factor Xa inhibitor drugs. The study will involve patients treated with rivaroxaban.
Partnership plans trial of antidote to Factor Xa inhibitors
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan